{
  "paper_id": "PMC11440802",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440802/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Fig. 1.",
      "caption": "A 67-year-old woman with left NST BC, ER+, PR+, HER2- (luminal A), with clinical axillary lymph nodes was referred for primary staging with [18F]FDG PET/CT. MIP PET images (A) showed numerous foci of [18F]FDG abnormal uptake. Sagittal view (B and C, CT and PET/CT fusion images) showed numerous bone osteolytic hypermetabolic metastases. Axial PET/CT fusion images showed the primary left breast cancer (D), axillary lymph nodes (E) and liver metastases (F). The disease was classified stage IV.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0cd/11440802/9824d514a3db/gr1.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0cd/11440802/9824d514a3db/gr1.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0cd/11440802/9824d514a3db/gr1.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0cd/11440802/9824d514a3db/gr1.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0cd/11440802/9824d514a3db/gr1.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC11440802/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0cd/11440802/9824d514a3db/gr1.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "A 56-year-old woman with NST BC, grade 2, ER+, PRâˆ’, HER2- (luminal B) with confirmed axillary lymph nodes involvement was submitted to primary surgery. Baseline PET/CT staging performed after surgery showed no pathological [18F]FDG uptake (A, whole body PET MIP image, and B, C, axial CT and PET/CT fusion images of the iliac bones). Two years later, the patient was referred for a new [18F]FDG PET/CT examination because of isolated CEA elevation. A single lytic metastasis of the right iliac bone (red arrows) was detected (D, whole body PET MIP image; and E, F, axial CT and PET/CT fusion images of the iliac bone). The patient was treated with stereotaxic radiotherapy and targeted therapy. Six months later, PET/CT showed a complete metabolic response (G, H, I). The focus of the right iliac bone was replaced by a non-[18F]FDG-avid osteosclerosis (blue arrows) suggestive of a healed lesion (H and I, axial views of CT and PET/CT fusion image).",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0cd/11440802/ca1a7821c1d1/gr2.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0cd/11440802/ca1a7821c1d1/gr2.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0cd/11440802/ca1a7821c1d1/gr2.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0cd/11440802/ca1a7821c1d1/gr2.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0cd/11440802/ca1a7821c1d1/gr2.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC11440802/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0cd/11440802/ca1a7821c1d1/gr2.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Recently, several studies have shown [18F]FDG PET/CT may be useful, not only in patients with LABC, but also in intermediate risk patients [[25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36]] (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Assessment of suspected locoregional and/or distant metastatic recurrence\nEarly detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Early detection and staging of recurrence are essential for optimal management. [18F]FDG PET/CT imaging offers high sensitivity in detecting BC relapse [[48], [49], [50], [51], [52], [53], [54], [55], [56], [57], [58], [59], [60], [61], [62], [63]] with higher performance than conventional imaging, whether suspected by clinical examination, conventional imaging, or tumor marker elevation (CA 15.3 or CEA) (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Changes in metabolic activity usually occur earlier than changes in tumor size. [18F]FDG PET/CT has been shown to be very effective in assessing the response to therapy of patients with MBC [40,[111], [112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129]], especially in assessing the response of bone lesions (Fig. 2) [[40], [129]].",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 2,
    "claims_count": 35,
    "images_downloaded": 2,
    "tables_filtered": 8
  }
}